Researchers at the University of Alabama at Birmingham published a new study in Science Translational Medicine showing that blocking sortilin binding significantly improves experimental progranulin gene therapy for frontotemporal dementia, offering a potential path to more effective treatments for a condition currently lacking a cure. Meanwhile, in related neurological and endocrine research contexts, studies examine conditions such as familial isolated pituitary adenoma (FIPA)—an inherited condition characterized by the development of a noncancerous tumor in the pituitary gland, which is found at the base of the brain and produces hormones that control many important body functions—as well as investigations that included 195 patients with pituitary adenoma (PA) and 235 age- and sex-matched healthy control subjects without a history of PA or other pituitary disorders, utilizing genomic DNA extracted from peripheral venous blood samples and genotyped using real-time polymerase chain reaction, with statistical analyses performed using R software (version 4.1.2).
Frontotemporal dementia is a progressive brain disorder typically emerging when individuals are in their fifties or sixties, triggering profound shifts in personality, behavior, and language. Certain forms of the disease stem from mutations in the GRN gene, which deplete critical supplies of a vital protein named progranulin. When those levels drop, the brain’s cellular recycling mechanism—the lysosome—begins to fail, driving neurodegeneration.
For years, laboratory investigations directed by Erik D. Roberson explored gene therapy to replenish progranulin inside the brain. Earlier experiments by the research team demonstrated that delivering the progranulin gene could ameliorate disease abnormalities in animal models, paving the way for clinical trials. Yet a fundamental question persisted regarding the design of the therapy itself.
Cargo Design and the Sortilin Receptor Discovery
When scientists seek to optimize gene therapies, attention usually centers on the delivery mechanism—selecting the viral vector, adjusting dosage, or targeting specific brain regions. Investigators wanted to know whether the design of the cargo protein itself carried equal weight. During prior work, researchers attached a small molecular tag to progranulin to trace its movement across the brain.
We later realized that the tag happened to sit right where progranulin attaches to a receptor called sortilin, and it blocked that interaction almost by accident,
Roberson explained. That accidental blockade left a lingering question about how much therapeutic success stemmed from progranulin alone versus the inhibition of sortilin.
“So, we had a question hanging over our original work: How much of our therapy’s success came from the progranulin itself, and how much came from that blockade of sortilin?”
Erik D. Roberson, M.D., Ph.D., professor and Rebecca Gale-Heersink Endowed Chair in the UAB Department of Neurology
To isolate the effect, the team constructed two distinct versions of the gene therapy. One variant permitted normal progranulin binding to sortilin, while the second blocked the interaction. Testing both approaches in animal models lacking progranulin revealed striking differences in therapeutic output.
Comparative Outcomes in Preclinical Models
The contrast between the two therapeutic designs proved substantial. When progranulin retained its capacity to bind sortilin normally, the therapy yielded lower protein concentrations, and that protein failed to disperse widely through the brain tissue.
The unblocked version fell short across multiple measures; it failed to calm inflamed immune cells, failed to normalize behavior, and failed to reduce blood markers indicating brain damage. In a different biomarker investigation, serum IL-33 concentrations were significantly higher in patients with PA than in controls (median (IQR): 7.57 (3.15) vs. 5.81 (3.27) pg/mL; p = 0.00026), though no significant associations were observed between serum IL-33 concentrations and the evaluated clinical characteristics such as tumour size, hormonal activity, invasiveness, and recurrence.
Conversely, blocking the sortilin interaction resolved those shortcomings entirely. The modified therapy generated higher progranulin expression and distributed the protein much farther across the brain. It also reduced harmful neuroinflammation, corrected lipid abnormalities linked to the disease, restored normal behavioral patterns measured via advanced machine-learning analysis, and lowered blood levels of neurofilament light chain—a recognized biomarker for nerve cell damage and disease progression.
Implications for Future Clinical Trials and Combined Strategies
The research highlights microglia, the brain’s resident immune cells, as a primary beneficiary. The modified gene therapy proved exceptionally effective at curbing microglial dysfunction and inflammation, processes increasingly recognized as major drivers of neurodegeneration in frontotemporal dementia.
Several progranulin gene therapies are currently undergoing evaluation in patients, and the findings suggest that subsequent iterations may achieve greater efficacy if engineered specifically to avoid binding sortilin. Furthermore, the work intersects with independent drug development efforts targeting sortilin through antibodies and small molecules.
As clinical investigations advance, researchers must determine how these insights translate from animal models into human treatments, keeping watch over how engineered protein modifications influence safety and long-term viral delivery persistence.